Pharmaceutical

Pfizer and Astellas seek updated EMA approval for Padcev with Keytruda

Results from a Phase III trial indicated that adding MSD’s blockbuster drug boosted survival rates in advanced bladder cancer patients.

Jan 29, 2024 - 18:00
Pfizer and Astellas seek updated EMA approval for Padcev with Keytruda
Results from a Phase III trial indicated that adding MSD’s blockbuster drug boosted survival rates in advanced bladder cancer patients.
Read the original article

Tags:

Previous Article

Moderna leads the development of mRNA vaccines in infectious diseases

Next Article

Merck is on the lookout for more opportunities within immunology

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Grifols prepares for late-stage plans with plasma-derived medicines in 2024

Grifols prepares for late-stage plans with plasma-deriv...

Feb 28, 2024

Mirum applies for extended use of PFIC therapy in Europe

Mirum applies for extended use of PFIC therapy in Europe

Apr 6, 2023

Key questions (and answers) about the historic approval of a CRISPR-based medicine

Key questions (and answers) about the historic approval...

Nov 17, 2023